Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 228,251,249 papers from all fields of science
Search
Sign In
Create Free Account
Recombinant MIP1-alpha Variant ECI301
Known as:
ECI301
, eMIP
A recombinant form of a human macrophage inflammatory protein-1 alpha (MIP1-alpha) with a substitution of aspartate to alanine at position 26, with…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
NCIt Antineoplastic Agent Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Maternal and perinatal outcomes and factors associated with twin pregnancies among preterm births: Evidence from the Brazilian Multicenter Study on Preterm Birth (EMIP)
Danielly S Santana
,
J. Cecatti
,
+8 authors
M. H. Sousa
International journal of gynaecology and…
2020
Corpus ID: 211024221
To compare maternal and perinatal outcomes between twin and single preterm births (PTB) and associated factors.
2018
2018
EC2.2 - Screen printed carbon electrodes incorporating electrochemical molecularly imprinted polymers to detect pollutant
H. Brisset
,
V. M. Ekomo
,
+4 authors
T. Noguer
2018
Corpus ID: 58938558
Electrochemical molecularly imprinted polymers (e-MIP) are MIP specially designed to detect organic molecules thanks to the…
Expand
2018
2018
Identification of the active portion of the CCL3 derivative reported to induce antitumor abscopal effect
T. Tsuchiya
,
K. Shiraishi
,
K. Nakagawa
,
Jae-Ryong Kim
,
S. Kanegasaki
Clinical and Translational Radiation Oncology
2018
Corpus ID: 49309205
2014
2014
Macrophage inflammatory protein derivative ECI301 enhances the alarmin-associated abscopal benefits of tumor radiotherapy.
S. Kanegasaki
,
K. Matsushima
,
K. Shiraishi
,
K. Nakagawa
,
T. Tsuchiya
Cancer Research
2014
Corpus ID: 586819
Radiotherapy can produce antitumor benefits beyond the local site of irradiation, an immune-based phenomenon known as the…
Expand
2014
2014
Alarmins released during local antitumor treatments play an essential role in enhancing tumor growth inhibition at treated and non-treated sites via a derivative of CCL3
S. Kanegasaki
,
T. Tsuchiya
Oncoimmunology
2014
Corpus ID: 14282170
ECI301 (eMIP), a single amino-acid substituted CCL3 (MIP-1α), enhanced tumor growth inhibition and the abscopal effect (an effect…
Expand
2013
2013
Rapid Method for Electron Tomographic Reconstruction and Three-Dimensional Modeling of the Murine Synapse Using an Automated Fiducial Marker-Free System
Hyun-wook Kim
,
S. Oh
,
Namkug Kim
,
E. Nakazawa
,
I. Rhyu
Microscopy and Microanalysis
2013
Corpus ID: 7865099
Abstract Electron tomography (ET) has recently afforded new insights into neuronal architecture. However, the tedious process of…
Expand
2008
2008
Evidence from a meta-analysis of Language Didactics research
Cristina Sá
,
Teresa Cardoso
,
Isabel Alarcão
,
Philippe Meirieu
,
J. Almeida
2008
Corpus ID: 49572231
I – Introduction Recent developments in Education reveal a shift from teaching to learning, supported by international…
Expand
Review
2001
Review
2001
Trimetazidine in AMI.
G. Lopaschuk
European Heart Journal
2001
Corpus ID: 33158645
I read with interest the paper by the EMIP-FR Group published in issue 18, Vol. 21, of the European Heart Journal, as well as the…
Expand
2000
2000
The EMIP Project
G. Tognoni
2000
Corpus ID: 71388485
The publication of the results of the European Myocardial Infarction Project – Free Radicals (EMIP–FR) on the shortand long-term…
Expand
1993
1993
Free radicals, reperfusion and myocardial infarction therapy: European Myocardial Infarction Project--free radicals pilot study. EMIP-FR Pilot Study Group.
European Heart Journal
1993
Corpus ID: 45490255
Reperfusion injury due to overproduction of free radicals may reduce the efficacy of thrombolytic therapy. Trimetazidine is an…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE